Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene in Kawasaki disease

가와사키병 환아에서 plasminogen activator inhibitor-1 유전자 다형성에 관한 연구

  • Han, Mi Young (Department of Pediatrics, College of Medicine, Kyunghee University)
  • 한미영 (경희대학교 의과대학 소아과학교실)
  • Received : 2007.04.11
  • Accepted : 2007.05.10
  • Published : 2007.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : To demonstrate genetic background of pathogenesis of Kawasaki disease (KD), I examined the genetic polymorphism of plasminogen activator inhibitor-1 (PAI-1) in KD patients. Methods : PCR-RFLP of PAI- 1 promotor gene was analyzed in 56 KD patients admitted to Kyunghee University Hospital, Gachon Medical School Gil Hospital, and Eulji Hospital from March to August 2000 and 206 normal control populations. Results : There were no differences in the genotype and allelic frequency of the PAI-1-675 (4G/5G) and PAI-1-844 (G/A) polymorphic site (which are located in the promoter region) between KD and control subjects. Also I could not detect any significant differences in specific genotypes between patients with the coronary artery lesion (CAL) and patients without CAL. Conclusion : No association was observed in -844 G/A and -675 4G/5G of PAI-1 gene polymorphism with KD.

목 적 : 가와사키병과 PAI-1의 유전자 다형성의 연관성에 대한 연구를 시행하여 가와사키병 발병의 유전적 배경을 알아보고자 하였다. 방 법 : 경희대학교 부속 병원, 가천의과대학 부속 길병원, 을지대학교 부속 노원 을지병원 소아과에 입원하여 가와사키병으로 진단되었던 환아 56명과 정상 대조군 206명을 대상으로 PAI-1 촉진자의 중합 효소 연쇄반응을 시행하고 분석하였다. 결 과 : 가와사키병 환자 군과 정상 대조 군을 비교하였을 때 PAI-1-675 4G/5G 유전자형과 PAI-1-844 G/A의 유전자형의 사이에서 유의한 차이가 없었다. 또한 일시적인 관상 동맥 합병증이 있는 환자 군과 합병증이 없는 환자 군간을 비교했을 때 PAI-1-675 유전형과 PAI-1-844 유전형간에 의미 있는 차이를 보이지 않았다. 결 론 : 가와사키병에서 PAI-1의 촉진자 부위의 -844 G/A와 -675 4G/5G의 유전자 다형성의 차이는 관찰되지 않았으며 PAI-1유전자 다형성이 가와사키병에 대한 감수성에 관여할 가능성이 희박함을 알 수 있었다.

Keywords

References

  1. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed MA. Diagnosis and therapy of Kawasaki disease. Circulation 1993;87:1776-80 https://doi.org/10.1161/01.CIR.87.5.1776
  2. Kato S, Kimura M, Tsuji K, Kusakawa S, Asai T, Juji T, et al. HLA antigens in Kawasaki disease. Pediatrics 1978; 61:252-5
  3. Ahn SY, Jang GC, Shin KM, Kim DS. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsei Med J 2003;44: 1021-6 https://doi.org/10.3349/ymj.2003.44.6.1021
  4. Chien YH, Chang KW, Yang YH, Lu MY, Lin YT, Chiang BL. Association between levels of TNF-alpha and TNFalpha promoter -308 A/A polymorphism in children with Kawasaki disease. J Formos Med Assoc 2003;102:147-50
  5. Sohn MH, Hur MW, Kim DS. Interleukin 6 gene promoter polymorphism is not associated with Kawasaki disease. Genes Immun 2001;2:357-62 https://doi.org/10.1038/sj.gene.6363785
  6. MacSweeney ST. Mechanical properties of abdominal aortic aneurysm and prediction of risk of rupture. Cardiovasc Surg 1999;7:158-9 https://doi.org/10.1016/S0967-2109(98)00145-8
  7. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitor in patients with Kawasaki disease. Circulation 2001;104:860-3 https://doi.org/10.1161/hc3301.095286
  8. Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, et al. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Pediatr Res 2003;53:983-8 https://doi.org/10.1203/01.PDR.0000061566.63383.F4
  9. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the committee on rheumatic Fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Circulation 1994;89:916-22 https://doi.org/10.1161/01.CIR.89.2.916
  10. Kim HS. Effects of Chungshimgunbi-tang on the expressions of tissue factor and the plasminogen activator inhibitor-1 gene (dissertation) Seoul: Univ. Kyunghee, 1998
  11. Mori M, Miyamae T, Kurosawa R, Yokota S, Onoki H. Two-generation Kawasaki disease: Mother and daughter. J Pediatrics 2001;139:754-6
  12. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin & Exp Immunol 2001;125:340-4 https://doi.org/10.1046/j.1365-2249.2001.01608.x
  13. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K, Johnsen M. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003;22:4389-97 https://doi.org/10.1038/sj.onc.1206601
  14. Lindholt JS, Jorgensen B, Shi GP, Henneberg EW. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J vasc Endovasc Surg 2003;25:546-51 https://doi.org/10.1053/ejvs.2002.1872
  15. Eriksson P, Kallin B, van't Hooft F, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen- activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5 https://doi.org/10.1073/pnas.92.6.1851
  16. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT, Reiner AP, et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovascular Risk 2002;9:131-7 https://doi.org/10.1097/00043798-200204000-00009
  17. Bottiger C, Koch W, Lahn C, Mehilli J, von Beckerath N, Schomig A, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 2003;146:855-61 https://doi.org/10.1016/S0002-8703(03)00363-6
  18. Chow KM, Szeto CC, Szeto CY, Poon P, Lai FM, Li PK. Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients. Transplantation 2002;74:1791-4